JW Pharmaceutical obtains first domestic patent for manufacturing technology of hair loss treatment 'Jaidat'

Development of Korea's First Dutasteride Tablet Formulation 'Jedaateu Tablet'
Promotion of Global CMO Business

[Asia Economy Reporter Myunghwan Lee] JW Pharmaceutical announced on the 9th that it has obtained a patent from the Korean Intellectual Property Office for the manufacturing technology of 'Jeidart Tablets (active ingredient Dutasteride),' a treatment for hair loss and benign prostatic hyperplasia.

Dutasteride tablets. / Photo by JW Choongwae Pharmaceutical Co., Ltd.

This patent relates to "solid formulations containing Dutasteride and methods for their manufacture," aiming to protect the product that succeeded in tablet formulation of Dutasteride for the first time in Korea. Patents have also been filed in more than 10 countries overseas, including the United States.

Dutasteride is an inhibitor of type 1 and 2 5-alpha-reductase enzymes involved in the production of dihydrotestosterone (DHT), a male hormone. It is effective in improving urinary disorders caused by benign prostatic hyperplasia and reducing symptoms such as acute urinary retention, and it also plays a role in preventing hair loss.

JW Pharmaceutical explained that Jeidart Tablets apply the poorly soluble drug delivery system 'SMEDDS,' which provides the same bioavailability as Dutasteride soft capsules. The SMEDDS technology solubilizes drugs with poor solubility to enhance rapid absorption in the body.

This product improves patient convenience by eliminating the discomfort of sticking to the mouth and esophagus, which commonly occurs with soft capsules. It also resolves issues such as leakage of contents caused by rupture of the gelatin film that encloses soft capsules.

JW Pharmaceutical launched the first Dutasteride tablet product in Korea, 'Jeidart Tablets 0.5 mg,' in November 2018, and is currently conducting contract manufacturing (CMO) business with 27 domestic pharmaceutical companies.

A JW Pharmaceutical official said, "The patent registration for Dutasteride tablets recognizes JW's competitiveness in formulation research technology," adding, "Compared to soft capsules, tablet formulations have advantages in developing high value-added products such as combination drugs, and we plan to actively promote not only domestic but also global CMO business in the future."